It is an immune system disorder that causes inflammation of the nerves and can cause pain, numbness, muscle weakness and difficulty walking
The EMA evaluates cases of Guillain-Barré syndrome (Gbs) reported after the administration of the AstraZeneca vaccine. The drug, recommended in Italy for the over 60s and already in the spotlight for thrombosis cases reported after the first dose, is still monitored by the Prac Pharmacovigilance Committee of the European Medicines Agency. This was reported by the EMA in the report in which it takes stock of the last meeting of the Prac. Gbs, reminds the EU regulatory body, is a disorder of the immune system that causes inflammation of the nerves and can cause pain, numbness, muscle weakness and difficulty in walking.
The experts of the committee, explains the EMA, are analyzing “the data provided by the holder of the marketing authorization”, Aic, of the Anglo-Swedish vaccine “on cases of Guillain-Barré syndrome reported following vaccination. Gbs was identified during the Aic process as a possible adverse event that requires specific monitoring activities “, the agency specifies. “The Prac – he underlines – has asked the holder of the marketing authorization to provide further detailed data, including an analysis of all reported cases, as part of the next safety report”. The committee will continue its review and provide further communications as new information becomes available.